RT Journal Article SR Electronic T1 Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer JF In Vivo JO In Vivo FD International Institute of Anticancer Research SP 1211 OP 1215 DO 10.21873/invivo.12371 VO 35 IS 2 A1 YASUYOSHI SATO A1 NAOKI FUKUDA A1 YU FUJIWARA A1 XIAOFEI WANG A1 TETSUYA URASAKI A1 AKIHIRO OHMOTO A1 KENJI NAKANO A1 MAKIKO ONO A1 JUNICHI TOMOMATSU A1 HIROKI MITANI A1 SHUNJI TAKAHASHI YR 2021 UL http://iv.iiarjournals.org/content/35/2/1211.abstract AB Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC), nivolumab conferred a survival benefit to patients. However, the best treatment sequence of chemotherapy and anti-PD-1/PD-L1 therapy in these cancers is unclear. Patients and Methods: This was an observational study using data collected prospectively from 97 HNC patients treated with nivolumab at our institutions. Twenty-two HNC patients who received paclitaxel-based chemotherapy before (pre-PTX, n=12) and after (post-PTX, n=10) nivolumab were evaluated. Results: The median follow-up time was 15.9 months (range=6.9-35.9 months). There was a significant difference in the overall response rate (ORR) between pre-PTX (17%) and post-PTX (70%) (p=0.027). Similarly, time to progression (TTP) was significantly longer after nivolumab than before nivolumab (post-PTX, 7.4 months; pre-PTX, 4.9 months, p=0.020). Conclusion: Paclitaxel-based chemotherapy had a better ORR and TTP after nivolumab than before nivolumab for HNC. The sequential administration of anti-PD-1 therapy followed by paclitaxel-based chemotherapy could be a better strategy for HNC.